No association between LDL receptor and <i>CETP</i> genetic variants and atorvastatin response in Jordanian hyperlipidemic patients-Reference-Cited by-同舟云学术

No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients

Published:2022-04-21 Issue:4 Volume:37 Page:369-374
ISSN:2363-8915
Container-title:Drug Metabolism and Personalized Therapy
language:en
Short-container-title:

Author:

Zihlif Malek¹,Otoum Suhad¹,Al Shhab Mohammad¹,Almadani Zaid¹,Momani Monther²,Alhawari Hussam²,Esraa jibrini ¹,Jarrar Yazun³,Al-ameer Hamzeh⁴,Imraish Amer⁵

Affiliation:

1. Department of Pharmacology , School of Medicine, The University of Jordan , Amman , Jordan

2. Department of Internal Medicine , School of Medicine, The University of Jordan , Amman , Jordan

3. Deprtmant of Pharmacy , College of Pharmacy, Al-Zaytoonah University of Jordan , Amman , Jordan

4. Department of Biology and Biotechnology , American University of Madaba , Madaba , Jordan

5. Department of Biological Sciences , School of Science, The University of Jordan , Amman , Jordan

Abstract

Abstract Objectives Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (CETP) and LDL receptor (LDLR) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR AvaII, CETP TaqIb, and Rs1532624 on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients. Methods One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of LDLR AvaII and CETP TaqIb genetic variants. The genotyping of CETP Rs1532624 variant was done by Sanger DNA-Sequencing. Results LDLR AvaII and CETP TaqIb and Rs1532624 variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy. Conclusions Results demonstrated a significant association between the LDLR AvaII and CETP TaqIb, and Rs1532624 genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.

Publisher

Walter de Gruyter GmbH

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

https://www.degruyter.com/document/doi/10.1515/dmpt-2021-0177/pdf

Reference22 articles.

1. Maitland-van der Zee, AH, Klungel, OH, Stricker, BH, Monique Verschuren, WM, Kastelein, JJ, Leufkens, HG, et al.. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213–22.

2. Mangravite, LM, Thorn, CF, Krauss, RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006;6:360–74.

3. Freitas, RN, Khaw, KT, Wu, K, Bowman, R, Jeffery, H, Luben, R, et al.. A single nucleotide polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene ( HMGCR) influences the serum triacylglycerol relationship with dietary fat and fibre in the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. Br J Nutr 2010;104:765–72.

4. Alhawari, H, Jarrar, Y, AlKhatib, MA, Alhawari, H, Momani, M, Zayed, A, et al.. The association of 3-hydroxy-3-methylglutaryl-CoA reductase, Apolipoprotein E, and solute carrier organic anion genetic variants with Atorvastatin response among Jordanian patients with Type 2 diabetes. Life (Basel) 2020;10:232.

5. Abdullah, S, Jarrar, Y, Alhawari, H, Abed, E, Zihlif, M. The influence of Endothelial Nitric Oxide Synthase (eNOS) genetic polymorphisms on cholesterol blood levels among Type 2 diabetic patients on Atorvastatin Therapy. Endocr Metab Immune Disord Drug Targets 2021;21:352–9.